当前位置： SCI文献检索 > CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY期刊下所有文献 > Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.

Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.

Abstract：

PURPOSE:To investigate timing of Yttrium-90 radioembolization (Y90) during treatment course, genomics, and other clinical factors as predictors of overall survival (OS) in colorectal liver metastasis (CRLM) that have progressed on at least one line of chemotherapy. MATERIALS AND METHODS:This was a retrospective study from 2013 to 2018 of patients with CRLM and genomic analysis prior to Y90 at a multihospital tertiary referral center. OS from liver metastasis diagnosis and predictors of OS were analyzed using Kaplan-Meier estimation with log-rank and Cox regression analyses. RESULTS:Overall, 58 patients with CRLM who progressed on at least one line of chemotherapy who had genomic analysis prior to Y90 were identified. Median OS after hepatic metastasis was 29.9 months. Of these, 16 (28%) patients received Y90 after failure of the first-line systemic chemotherapy. There was significantly prolonged OS in patients receiving Y90 immediately following failure of the first-line chemotherapy folinic acid, fluorouracil, oxaliplatin ((FOLFOX) ± bevacizumab) versus following multiple lines of chemotherapy (median OS of 46.3 vs. 26.6 months, P = 0.005). The presence of genetic mutation in tumor, MAPK pathway wild type, left-sided primary tumor, low MELD score, and non-diffuse unilobar disease were also found to be predictors prolonged survival on log-rank analysis (P's < 0.05). On multivariate analysis, receiving Y90 after failure of the first line of chemotherapy, low baseline MELD score, and baseline ECOG performance score of 0 were all found to be independent predictors of prolonged OS from the time of metastatic disease diagnosis (P's < 0.05). CONCLUSION:In patients with CRLM, receiving Y90 after failing the first line of chemotherapy, lack of genetic mutation, low MELD score, and lower tumor burden appear to be independent predictors of prolonged OS. LEVEL OF EVIDENCE:Level 4, case-control study.

journal_name

Cardiovasc Intervent Radiol

journal_title

Cardiovascular and interventional radiology

authors

Dabrowiecki A,Sankhla T,Shinn K,Bercu ZL,Ermentrout M,Shaib W,Cardona K,Newsome J,Kokabi N

doi

10.1007/s00270-020-02463-z

subject

Has Abstract

pub_date

2020-07-01 00:00:00

pages

1006-1014

issue

eissn

0174-1551

issn

1432-086X

pii

10.1007/s00270-020-02463-z

journal_volume

pub_type

杂志文章,多中心研究

在线工具

Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.